New approach for treating recurrent prostate cancer on the horizon

June 15, 2009,

A new study shows that an alpha-particle emitting radiopeptide—radioactive material bound to a synthetic peptide, a component of protein—is effective for treating prostate cancer in mice, according to researchers. The results could eventually result in a significant breakthrough in prostate cancer treatment, especially for patients whose cancer recurs after the prostate is removed.

"Our study shows that this novel form of treatment has the potential to target and destroy with minimal damage to surrounding healthy tissue," said Damian Wild, University Hospital Basel, Basel, Switzerland, lead author of the study. "Eventually, this therapy could give hope to some of the hardest-to-treat patients and also could be applied to other types of cancer."

Every year, more than 186,000 men in the United States are newly diagnosed with prostate cancer. The most common types of treatment include surgical removal of some, or all, of the prostate, followed by radiation therapy. More than 30,000 men each year who have had their prostates removed experience recurrence of the cancer. In most of these cases, the disease cannot be localized and treated adequately with conventional treatments; therefore, a systemic treatment that efficiently kills small tumors is needed.

Because tumor cells readily bind with certain peptides, researchers have been able to develop highly specific radiopeptides that bind with and treat them using specific therapeutic radioactive substances attached to the radiopeptide. Prostate cancer cells—and many other types of cancer cells—have an overabundance of gastrin-releasing peptide receptors, making the cancer a strong candidate for treatment with radiopeptides.

The study compared two different types of radiopeptides. One group of mice was injected with 213 Bi-DOTA-PESIN, which emits alpha particles that are effective at killing cancer cells. The other group was injected with beta-emitting 177 Lu-DOTA-PESIN, which are also effective in tumor cell-killing, but can also cause damage to nearby healthy cells. Alpha particles are able to kill cancer cells without damaging surrounding healthy tissue. A third group of mice received no treatment.

However, at the maximum tolerated dose, the alpha-emitting 213 Bi-DOTA PESIN was significantly more effective, tripling the survival rate of the mice that received the therapy. The results indicate that the alpha-emitting radiopeptide could provide a new approach for treating prostate cancer and eventually other types of cancer.

Source: Society of Nuclear Medicine (news : web)

Related Stories

Recommended for you

Stem cell vaccine immunizes lab mice against multiple cancers

February 15, 2018
Stanford University researchers report that injecting mice with inactivated induced pluripotent stem cells (iPSCs) launched a strong immune response against breast, lung, and skin cancers. The vaccine also prevented relapses ...

Induced pluripotent stem cells could serve as cancer vaccine, researchers say

February 15, 2018
Induced pluripotent stem cells, or iPS cells, are a keystone of regenerative medicine. Outside the body, they can be coaxed to become many different types of cells and tissues that can help repair damage due to trauma or ...

Team paves the way to the use of immunotherapy to treat aggressive colon tumors

February 15, 2018
In a short space of time, immunotherapy against cancer cells has become a powerful approach to treat cancers such as melanoma and lung cancer. However, to date, most colon tumours appeared to be unresponsive to this kind ...

Can our genes help predict how women respond to ovarian cancer treatment?

February 15, 2018
Research has identified gene variants that play a significant role in how women with ovarian cancer process chemotherapy.

First comparison of common breast cancer tests finds varied accuracy of predictions

February 15, 2018
Commercially-available prognostic breast cancer tests show significant variation in their abilities to predict disease recurrence, according to a study led by Queen Mary University of London of nearly 800 postmenopausal women.

Catching up to brain cancer: Researchers develop accurate model of how aggressive cancer cells move and spread

February 15, 2018
A brief chat at a Faculty Senate meeting put two University of Delaware researchers onto an idea that could be of great value to cancer researchers.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.